A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
ChromaDex highlights additional clinical and preclinical research strengthening science and understanding behind Niagen® (patented nicotinamide riboside) LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the results of several new studies, which have...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Mon., May 11, 2020 at 4:30 p.m. ET to discuss its financial results for the first quarter ended Mar. 31, 2020. The financial results will be reported in a press release after...
ChromaDex announces exclusive retail partnership with Superdrug UK, entering the European market and driving global expansion of Tru Niagen® LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with A.S. Watson Group into...
ChromaDex and A.S. Watson Group launch new Tru Niagen® Beauty in Watsons Hong Kong stores and online LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its new Tru Niagen® Beauty cellular health and beauty daily supplement...
Preclinical research from Dr. Charles Brenner and a team of leading scientists from three US universities concludes that key steps in coronavirus infection and innate immunity involve a tug-of-war with cellular NAD LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global...
ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia LOS ANGELES, March 23, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce launch of Tru Niagen® in Australia with distribution partner Matakana Health Limited...
LOS ANGELES, March 12, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19. There are no published...
Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018 Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency year-over-year.Tru Niagen® net sales of $10.2 million, a 57% increase year-over-year.Net loss...
Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal modelsLOS ANGELES, Feb. 27, 2020 -- ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine...
LOS ANGELES, Feb. 25, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended Dec. 31, 2019. The financial results will be reported in a...